



THE STUDY OF GENOMIC VARIATION OF BRCA GENES IN THE ALBANIAN POPULATION

PhD Student: Blerta Laze

Supervisor: Assoc. Prof. Dr. Merita Xhetani

38 Cycle - A.Y. 2023/2024

According to the Global Cancer Observatory, breast cancer is the most commonly cancer in women in Europe and Albania. The BRCA 1 and BRCA 2 are two essential tumour suppressor genes with a central role in the homologous recombination repair (HRR) pathway. According to many studies on genome populations, BRCA genes are considered polymorphic and revealed approximately 70.000 variants. Also, they suggest that BRCA variants are highly deleterious in damaging BRCA function, causing genome instability and increased cancer risk, affecting mostly breast and ovaries. This study aims to investigate the spectrum of BRCA1 and BRCA2 genetic variants in female Albanian population and to analyze the mutations significance from an evolutionary perspective. This is the first study conducted in Albania for the identification of BRCA gene variants, part of an ongoing project on Biomarkers in Rare Genetic Diseases in Albania, of the NanoAlb research group. The national screening of women for breast cancer is done through imaging techniques at Obstetrics and Gynecological University Hospital (Queen Geraldina), in Tirana, Albania (almost 600 tests/year). This allows the coordination of the work, through examinations and/or interviews, to identify the target group (with family breast cancer history). BRCA gene variants will be identified through Multiplex Ligation Probe Assay (MLPA) and fragment analysis will be done with SeqStudio genetic analyser. This variants will be compared with the documented identified variants in gnomAD browser database (recently ExAC data is available in the gnomAD browser) and BRCA Exchange data, to define the pathogenic variants. Actually, a family of 6 women members, already identified by MLPA assay with a deletion in exon 11 of BRCA1 gene, will be included in the positive control group. These tests demonstrated the existence of an autosomal dominant pattern of inheritance of the breast cancer cases, that is already confirmed by other studies. Furthermore, extensive studies suggest that BRCA genes vary by ethnicity. This is very important to study in Albanian population, as this country has its unique genetic, linguistic, and cultural features. Evolution factors contributed to this ethnic specificity, which include the positive selection imposed on human BRCA genes, the adaptation of different ethnic populations to their living environment, the bottleneck and founder effects, will also be involved in this study. As the studies suggest, this investigation is of highly importance in providing genetic evidences to understand the relationship between human evolution and cancer risk. Finally, this study may contribute to provide an overview of Albanian population for the BRCA variation genes and a comprehensive reference for clinical applications in the era of precising medicine.



References

- Dombernowsky SL., Weischer M., Freiberg JJ., Bojesen SE., Tybjaerg-Hansen A., Nordestgaard BG. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. *Cancer Epidemiol Biomarkers.* (2009); 18:2339–<https://doi.org/10.1158/1055-9965.EPI-09-0447>.
- Fernández-Lopez J. C1., Romero-Córdoba. S1., Rebollar-Vega. R1., Alfaro-Ruiz. L. A1., Jiménez-Morales. S1., Beltrán-Anaya. F1., Arellano-Llamas. R1., Cedro-Tanda. A1., Rios-Romero. M1., Ramirez-Florencio. M1., Bautista-Piña. V2., Dominguez-Reyes. C2., Villegas-Carlos. F2., Tenorio-Torres. A2. and Hidalgo-Miranda. A1*. Population and breast cancer patients' analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population. *Human Genomics.* (2019);13:3. <https://doi.org/10.1186/s40246-018-0188-9>.
- Ficarazzi. F., Vecchi. M., Ferrari. M. A., Pierotti. M. Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives. *The Breast.* (2021); 58: 121-129. doi:<https://doi.org/10.1016/j.breast.2021.04.011>.
- King. M-C., Levy-Lahad. E., Lahad. A. Population-Based Screening for BRCA1 and BRCA2. Lasker Award. American Medical Association. (2014); 312(11): 1091-1092. doi:10.1001/jama.2014.12483.
- Kostovska. I. M., Jakovchevska. S., Özdemir. M. J., Kiprijanovska. S., Kubelka-Sabit. K., Jasar. D., Iljovska. M., Lazareva. E., Smichkoska. S., Plaseska-Karanfilska. D. The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo. *Rep Pract Oncol Radiother.* (2022); 27(2): 303–309. doi: 10.5603/RPOR.a2022.0030.
- Ladan. M. M., Van Gent. D. C., Jager. A. Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation *Cancers.* (2021); 13(5)1004. <https://doi.org/10.3390/cancers13051004>.
- Lippi. G., Mattiuzzi. C., Montagnana. M. BRCA population screening for predicting breast cancer: for or against? *Annals of Translational Medicine.* (2017); 5(13): 275. doi: 10.21037/atm.2017.06.71.
- Panneerselvam. J., Qu. D., Houchen. C., Bronze. M., Chandrakesan. P. DCLK1 and DNA Damage Response. Book; *Genotoxicity and Mutagenicity.* (2020); 10.5772/intechopen.92327.
- Ricks-Santi LJ., Nie J., Marian C., Ochs-Balcom HM., Trevisan M., Edge SB., Kanaan Y., Freudenheim JL., Shields P. G. BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study. *Genet Epidemiol.* (2013); 37:504. <https://doi.org/10.1002/gepi.21730>.
- Singh. A. K., Yu. X. Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers. *Trends Cancer.* (2020); Jul; 6(7):559-568.7. doi:<https://doi.org/10.1016/j.trecan.2020.03.004>.
- Wang. S. M. A global perspective on the ethnic-specific BRCA variation and its implication in clinical application. *Journal of the National Cancer Center.* (2023); Vol 3, Issue 1, Pages 14-20.
- Xu. G-P., Zhao Q., Wang. D., Xie. W-Y., Zhang. L-J., Zhou. H., Chen. Sh-Zh., and Wu. L-F. The association between BRCA1 gene polymorphism and cancer risk: a meta-analysis. *Oncotarget.* (2018); Feb 2; 9(9): 8681–8694. doi: 10.18632/oncotarget.24064.